<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00749385</url>
  </required_header>
  <id_info>
    <org_study_id>PN400-114</org_study_id>
    <nct_id>NCT00749385</nct_id>
  </id_info>
  <brief_title>A Pharmacokinetic (PK) Study Evaluating Naproxen and Esomeprazole Plasma Levels</brief_title>
  <official_title>A Randomized, Open-Label, 4-Way Crossover Study to Evaluate Naproxen and Esomeprazole Plasma Levels in Healthy Subjects Following Oral Administration of PN 400, Enteric-Coated Naproxen 500mg Plus Enteric-Coated Esomeprazole 20mg, Enteric-Coated Naproxen 500mg Alone, and Enteric-Coated Esomeprazole 20mg Alone.</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>POZEN</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>POZEN</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      A pharmacokinetic study evaluating naproxen and esomeprazole blood levels in 4 treatments,
      each containing one or both components.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This study is being conducted to assess the relative bioavailability of naproxen and
      esomeprazole from a single dose of PN 400 (delayed-release naproxen 500mg / immediate-release
      esomeprazole 20mg), enteric-coated naproxen 500mg co-administered with enteric-coated
      esomeprazole 20mg, enteric-coated naproxen 500mg administered alone, and enteric-coated
      esomeprazole 20mg administered alone.
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>August 2008</start_date>
  <completion_date type="Actual">October 2008</completion_date>
  <primary_completion_date type="Actual">October 2008</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>To assess the single-dose pharmacokinetics and relative bioavailability of esomeprazole in PN 400 (naproxen 500mg / esomeprazole 20mg), the enteric-coated (EC) naproxen 500mg plus EC esomeprazole 20mg and the EC esomeprazole 20mg alone treatments</measure>
    <time_frame>12-72 hour PK assessments</time_frame>
  </primary_outcome>
  <secondary_outcome>
    <measure>To assess the single-dose pharmacokinetics and relative bioavailability of naproxen in PN 400 (naproxen 500mg / esomeprazole 20mg, the EC naproxen 500mg plus EC esomeprazole 20mg, and the EC naproxen 500mg alone treatments.</measure>
    <time_frame>72-hour PK assessments</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>To evaluate the safety of each of the single-dose treatments</measure>
    <time_frame>Entire study duration (48 days)</time_frame>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Actual">40</enrollment>
  <condition>Arthritis</condition>
  <arm_group>
    <arm_group_label>1</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>PN 400</description>
  </arm_group>
  <arm_group>
    <arm_group_label>2</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule(20mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>3</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Enteric-coated naproxen tablet (500mg)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>4</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>EC esomeprazole capsule (20mg)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>PN 400</intervention_name>
    <description>A single tablet containing delayed-release naproxen (500mg) plus immediate-release esomeprazole (20mg)</description>
    <arm_group_label>1</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC naproxen plus EC esomeprazole</intervention_name>
    <description>Enteric-coated naproxen tablet (500mg) plus enteric-coated esomeprazole capsule (20mg)</description>
    <arm_group_label>2</arm_group_label>
    <other_name>EC Naprosyn and Nexium</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC naproxen</intervention_name>
    <description>Enteric-coated naproxen tablet (500mg)</description>
    <arm_group_label>3</arm_group_label>
    <other_name>EC Naprosyn</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>EC esomeprazole</intervention_name>
    <description>Enteric-coated esomeprazole capsule (20mg)</description>
    <arm_group_label>4</arm_group_label>
    <other_name>Nexium</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Healthy males and non-pregnant, non-lactating females who are either of
             non-childbearing potential or using an acceptable method of birth control.

        Exclusion Criteria:

          -  Standard exclusion criteria for a study of this nature - no significant medical
             conditions that might affect the interpretation of the PK data or compromise the
             safety of the subject.
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <location>
    <facility>
      <name>PPD</name>
      <address>
        <city>Austin</city>
        <state>Texas</state>
        <zip>78744</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2008</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>September 5, 2008</study_first_submitted>
  <study_first_submitted_qc>September 8, 2008</study_first_submitted_qc>
  <study_first_posted type="Estimate">September 9, 2008</study_first_posted>
  <last_update_submitted>December 19, 2008</last_update_submitted>
  <last_update_submitted_qc>December 19, 2008</last_update_submitted_qc>
  <last_update_posted type="Estimate">December 23, 2008</last_update_posted>
  <responsible_party>
    <name_title>David Taylor</name_title>
    <organization>POZEN</organization>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Esomeprazole</mesh_term>
    <mesh_term>Naproxen</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

